Tags

Type your tag names separated by a space and hit enter

Pilot study of omega-3 fatty acid supplements in sickle cell disease.
APMIS. 2011 Jul; 119(7):442-8.A

Abstract

In a previous retrospective study, it was observed that the greater the amounts of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the blood, the lesser the number of complications of sickle cell disease (SCD) and the higher the steady state haemoglobin level. SCD causes ischaemia-reperfusion injury and inflammation; which can be ameliorated by a metabolite of DHA that down-regulates expression of pro-inflammatory genes. The objectives of this prospective pilot study were to evaluate the effects of DHA and EPA supplements in SCD, and test the hypothesis that these effects are mediated partly by reducing inflammation. Oral DHA and EPA supplements were given to 16 SCD patients for 6 months. We then compared pre- and post-supplementation values of number of crisis, steady state Hb, plasma unconjugated bilirubin and three indices of inflammation: plasma interleukin-6, blood neutrophil and platelet counts. There was a significant reduction in the plasma level of unconjugated bilirubin, and the number of sickle cell crisis; but not in the markers of inflammation. The pilot data suggest that DHA and EPA supplements reduce the number of crisis and steady state haemolysis in SCD; but provide no evidence that these effects are mediated by reducing inflammation.

Authors+Show Affiliations

University of Nigeria Teaching Hospital, College of Medicine, Enugu Campus, Nigeria. iheanyi.okpala@unn.edu.ngNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

21635551

Citation

Okpala, Iheanyi, et al. "Pilot Study of Omega-3 Fatty Acid Supplements in Sickle Cell Disease." APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, vol. 119, no. 7, 2011, pp. 442-8.
Okpala I, Ibegbulam O, Duru A, et al. Pilot study of omega-3 fatty acid supplements in sickle cell disease. APMIS. 2011;119(7):442-8.
Okpala, I., Ibegbulam, O., Duru, A., Ocheni, S., Emodi, I., Ikefuna, A., Umar, G., Asinobi, I., Madu, A., Okoye, A., Nwagha, T., Oguonu, U., Uamai, I., Agwu, O., Nonyelu, C., Anike, U., Agu, K., Anigbo, C., Chukwura, A., ... Herrada, S. (2011). Pilot study of omega-3 fatty acid supplements in sickle cell disease. APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 119(7), 442-8. https://doi.org/10.1111/j.1600-0463.2011.02751.x
Okpala I, et al. Pilot Study of Omega-3 Fatty Acid Supplements in Sickle Cell Disease. APMIS. 2011;119(7):442-8. PubMed PMID: 21635551.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pilot study of omega-3 fatty acid supplements in sickle cell disease. AU - Okpala,Iheanyi, AU - Ibegbulam,Obike, AU - Duru,Augustine, AU - Ocheni,Sunday, AU - Emodi,Ifeoma, AU - Ikefuna,Anthony, AU - Umar,Garba, AU - Asinobi,Isaac, AU - Madu,Anazoeze, AU - Okoye,Augustine, AU - Nwagha,Tessy, AU - Oguonu,Uche, AU - Uamai,Ify, AU - Agwu,Obineche, AU - Nonyelu,Charles, AU - Anike,Uche, AU - Agu,Kingsley, AU - Anigbo,Chukwudi, AU - Chukwura,Awele, AU - Ugwu,Ogechukwu, AU - Herrada,Sagrario, Y1 - 2011/04/17/ PY - 2011/6/4/entrez PY - 2011/6/4/pubmed PY - 2011/8/9/medline SP - 442 EP - 8 JF - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica JO - APMIS VL - 119 IS - 7 N2 - In a previous retrospective study, it was observed that the greater the amounts of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the blood, the lesser the number of complications of sickle cell disease (SCD) and the higher the steady state haemoglobin level. SCD causes ischaemia-reperfusion injury and inflammation; which can be ameliorated by a metabolite of DHA that down-regulates expression of pro-inflammatory genes. The objectives of this prospective pilot study were to evaluate the effects of DHA and EPA supplements in SCD, and test the hypothesis that these effects are mediated partly by reducing inflammation. Oral DHA and EPA supplements were given to 16 SCD patients for 6 months. We then compared pre- and post-supplementation values of number of crisis, steady state Hb, plasma unconjugated bilirubin and three indices of inflammation: plasma interleukin-6, blood neutrophil and platelet counts. There was a significant reduction in the plasma level of unconjugated bilirubin, and the number of sickle cell crisis; but not in the markers of inflammation. The pilot data suggest that DHA and EPA supplements reduce the number of crisis and steady state haemolysis in SCD; but provide no evidence that these effects are mediated by reducing inflammation. SN - 1600-0463 UR - https://www.unboundmedicine.com/medline/citation/21635551/Pilot_study_of_omega_3_fatty_acid_supplements_in_sickle_cell_disease_ L2 - https://doi.org/10.1111/j.1600-0463.2011.02751.x DB - PRIME DP - Unbound Medicine ER -